

Serial No. 09/280,567

**Claim Amendments**

Please cancel pending claims ~~1-3, 6, and 36-39~~ and add Claims 40-43.

Claims 1-3, 6, 36-39 (canceled).

---

Claim 40 (new): A method of treating an individual suffering from acute liver failure, comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO: 6 or SEQ ID NO: 8 to said individual.

Claim 41 (new): A method of treating an individual suffering from inflammation of the liver, comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO: 6 or SEQ ID NO: 8 to said individual.

Claim 42 (new): A method of treating an individual suffering from abnormal hepatocyte apoptosis, comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO: 6 or SEQ ID NO: 8 to said individual.

Claim 43 (new): A method of treating an individual suffering from hepatitis, comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO: 6 or SEQ ID NO: 8 to said individual.

---

**Specification Amendments:**

With reference to the page numbering of the substitute specification filed on 11/7/02 (Paper 29):

At page 6, lines 18 and 19, delete "Figure 8 shows reduction in B16 melanoma tumor volume in response to treatment with mFLINT."

✓ At page 6, line 5, change "Figure 2" to --Figure 2A-2B--;

✓ line 9, change "Figure 4" to --Figure 4A-4B--;

✓ line 20, change "Figure 9" to --Figure 8--;

✓ line 22, change "Figure 10" to --Figure 9--.

✓ At page 8, line 16, change "Figure 2" to --Figure 2A-2B--;

✓ line 21, change "Figure 4" to --Figure 4A-4B--;

✓ line 22, change "Figure 2" to --Figure 2A-2B--;

✓ line 24, change "and 4" to --and 4A-4B--.

✓ At page 56, line 25, delete "These data are shown graphically in Figure 8."

✓ line 25, delete "As shown in Figure 8,"

✓ line 25, change "tumor" to --Tumor--.

**Drawing Amendments**

The Draftsman issued a review dated March 24, 2003, objecting to the labelings of Figures 2 and 4, the left margin of Figures 3 and 5 and the character of the lines of Figure 8. Upon Applicants' review of Figure 3, there appears to be no violation of the margin requirement and we were unable to reach the reviewer for clarification. However, Figure 6 has a narrow bottom margin; therefore, it is possible that the Draftsman meant to indicate an unacceptable margin for Figure 6 instead of Figure 3. Figure 5 has an adequate left margin, but a narrow bottom margin.

Applicants request that present Figure 8 be deleted without prejudice. The information in Figure 8 is not related to the claims presently being pursued and is also described in the specification (Example 20, page 56) in such detail that Figure 8 is not required. Present Figures 9 and 10 have therefore been renumbered as Figures 8 and 9 respectively in the replacement figures submitted herein. Corresponding amendments to the specification to reflect this numbering change are requested herein. Applicants submit herein corrected, replacement Figures 2A, 2B, 4A, 4B, 5, 6, 8 and 9

Figures 2 and 4 contain nucleotide and protein sequence. Each of these figures spans two pages. The Examiner has instructed Applicants to label the two pages of each figure as "A" and "B" accordingly. Therefore Applicants submit herein Figures 2A and 2B to replace the present Figure 2. Likewise, Applicants submit herein Figures 4A and 4B to replace the present Figure 4. Additionally, submitted herein are corresponding amendments in the specification to reflect this Figure numbering change.

Figures 3 and 5 were objected to by the Draftsperson for having an incorrect left margin. MPEP 1825 PCT Rule 11.6 indicates that the left side margin minimally be 2.5 cm. The present Figures 3 and 5 have an adequate left margin. However, Figures 5 and 6 have a narrow bottom margin. MPEP 1825 PCT Rule 11.6 indicates that the bottom margin minimally be 1.0 cm. Replacement Figures 5 and 6 submitted herein have an adequate bottom margin. Applicants believe that the present Figure 3 meets all margin requirements and request that the present Figure 3 be accepted without modification.

Figure 8 was objected to by the Draftsperson for having lines that were not well defined and characters that were not plain and legible. Applicants request that Figure 8 be deleted without prejudice. Substitute, corrected Figures 8 and 9 with this numbering change reflected in the Figure label are submitted herein. Additionally, submitted herein are

Serial No. 09/280,567

corresponding amendments to the specification to reflect this Figure numbering change.

Applicants submit that no new matter has been added by these Figure amendments and that all Figures now are in condition for acceptance.